Develops a cancer drug in clinical trials for people with non-small cell lung cancer and is studying it for other cancers.
10-K for FY2025, filed Mar 23, 2026
No revenue reported yet.
10-K for FY2024, filed Mar 21, 2025
10-Q for Q3 FY2026, filed Nov 9, 2026
−$7.2MView ↗
Competes with Merck, Regeneron, Eli Lilly, and Roche
10-K for FY2025, filed Mar 23, 2026Any therapeutic candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies…View ↗
Loading...